New pill shows promise for Hard-to-Treat ovarian cancer
NCT ID NCT06084416
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 1b trial tests an experimental oral drug called sovilnesib in 120 people with advanced high-grade serous ovarian cancer that has stopped responding to standard platinum chemotherapy. The goal is to find the safest and most effective dose while monitoring side effects and tumor response. Participants take sovilnesib tablets by mouth, and the study will measure how well the drug controls the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sovilnesib (an oral KIF18A inhibitor)
What this could lead to
If successful, this could lead to a new oral treatment option for advanced ovarian cancer that has stopped responding to platinum-based chemotherapy.
What could go wrong
This is an early phase 1b trial with only 120 participants, so the drug may not prove effective or may have significant side effects. It is not a cure and aims to control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Corewell Health
Grand Rapids, Michigan, 49503, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
-
Georgia Cancer Center Augusta University
Atlanta, Georgia, 30912, United States
-
Hoag Memorial Hospital
Newport Beach, California, 92663, United States
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10128, United States
-
Johns Hopkins Hospital
Baltimore, Maryland, 21287, United States
-
MUSC Hollings Cancer Center
Charleston, South Carolina, 29020, United States
-
OU Health Stephenson Cancer Center
Oklahoma City, Oklahoma, 73117, United States
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14263, United States
-
The University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
-
UCLA
Los Angeles, California, 90095, United States
-
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205, United States